Selected research
Industry Research
Cancer Angiogenesis Inhibitors Industry Research Report 2026
Market perspective
The global Cancer Angiogenesis Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Angiogenesis Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Angiogenesis Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Angiogenesis Inhibitors include Novartis, Neumedicines, Marsala Biotech, Mabtech, Levolta Pharmaceuticals, Kyowa Hakko Kirin, Intas Pharmaceuticals, ImClone Systems and Hetero Drugs, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Angiogenesis Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Angiogenesis Inhibitors Market by Company
Novartis
Neumedicines
Marsala Biotech
Mabtech
Levolta Pharmaceuticals
Kyowa Hakko Kirin
Intas Pharmaceuticals
ImClone Systems
Hetero Drugs
Genexine
Genentech
Fuji Film Kyowa Kirin Biologics
Five Prime Therapeutics
Cancer Angiogenesis Inhibitors Segment by Type
Oncogene Targeted Therapy
Matrix Degrading & Remodeling Targeted Therapy
VEGF Targeted Therapy
FGF Targeted Therapies
Others
Cancer Angiogenesis Inhibitors Segment by Application
Ocular Neovascularization
Interferon Alpha-2α
Cancer
Cancer Angiogenesis Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Angiogenesis Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Angiogenesis Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Angiogenesis Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Angiogenesis Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Angiogenesis Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Angiogenesis Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oncogene Targeted Therapy
- Matrix Degrading & Remodeling Targeted Therapy
- VEGF Targeted Therapy
- FGF Targeted Therapies
- Others
Applications
- Ocular Neovascularization
- Interferon Alpha-2α
- Cancer
Companies covered
- Novartis
- Neumedicines
- Marsala Biotech
- Mabtech
- Levolta Pharmaceuticals
- Kyowa Hakko Kirin
- Intas Pharmaceuticals
- ImClone Systems
- Hetero Drugs
- Genexine
- Genentech
- Fuji Film Kyowa Kirin Biologics
- Five Prime Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Angiogenesis Inhibitors Market Size (2021-2032)
- 2.2.2 Global Cancer Angiogenesis Inhibitors Sales (2021-2032)
- 2.2.3 Global Cancer Angiogenesis Inhibitors Market Average Price (2021-2032)
- 2.3 Cancer Angiogenesis Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oncogene Targeted Therapy
- 2.3.3 Matrix Degrading & Remodeling Targeted Therapy
- 2.3.4 VEGF Targeted Therapy
- 2.3.5 FGF Targeted Therapies
- 2.3.6 Others
- 2.4 Cancer Angiogenesis Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ocular Neovascularization
- 2.4.3 Interferon Alpha-2α
- 2.4.4 Cancer
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Angiogenesis Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Angiogenesis Inhibitors Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cancer Angiogenesis Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Angiogenesis Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Angiogenesis Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Angiogenesis Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Angiogenesis Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Cancer Angiogenesis Inhibitors, Established Date
- 3.9 Global Cancer Angiogenesis Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Cancer Angiogenesis Inhibitors Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Neumedicines
- 4.2.1 Neumedicines Company Information
- 4.2.2 Neumedicines Business Overview
- 4.2.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio
- 4.2.5 Neumedicines Recent Developments
- 4.3 Marsala Biotech
- 4.3.1 Marsala Biotech Company Information
- 4.3.2 Marsala Biotech Business Overview
- 4.3.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio
- 4.3.5 Marsala Biotech Recent Developments
- 4.4 Mabtech
- 4.4.1 Mabtech Company Information
- 4.4.2 Mabtech Business Overview
- 4.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mabtech Cancer Angiogenesis Inhibitors Product Portfolio
- 4.4.5 Mabtech Recent Developments
- 4.5 Levolta Pharmaceuticals
- 4.5.1 Levolta Pharmaceuticals Company Information
- 4.5.2 Levolta Pharmaceuticals Business Overview
- 4.5.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
- 4.5.5 Levolta Pharmaceuticals Recent Developments
- 4.6 Kyowa Hakko Kirin
- 4.6.1 Kyowa Hakko Kirin Company Information
- 4.6.2 Kyowa Hakko Kirin Business Overview
- 4.6.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio
- 4.6.5 Kyowa Hakko Kirin Recent Developments
- 4.7 Intas Pharmaceuticals
- 4.7.1 Intas Pharmaceuticals Company Information
- 4.7.2 Intas Pharmaceuticals Business Overview
- 4.7.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
- 4.7.5 Intas Pharmaceuticals Recent Developments
- 4.8 ImClone Systems
- 4.8.1 ImClone Systems Company Information
- 4.8.2 ImClone Systems Business Overview
- 4.8.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio
- 4.8.5 ImClone Systems Recent Developments
- 4.9 Hetero Drugs
- 4.9.1 Hetero Drugs Company Information
- 4.9.2 Hetero Drugs Business Overview
- 4.9.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio
- 4.9.5 Hetero Drugs Recent Developments
- 4.10 Genexine
- 4.10.1 Genexine Company Information
- 4.10.2 Genexine Business Overview
- 4.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Genexine Cancer Angiogenesis Inhibitors Product Portfolio
- 4.10.5 Genexine Recent Developments
- 4.11 Genentech
- 4.11.1 Genentech Company Information
- 4.11.2 Genentech Business Overview
- 4.11.3 Genentech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Genentech Cancer Angiogenesis Inhibitors Product Portfolio
- 4.11.5 Genentech Recent Developments
- 4.12 Fuji Film Kyowa Kirin Biologics
- 4.12.1 Fuji Film Kyowa Kirin Biologics Company Information
- 4.12.2 Fuji Film Kyowa Kirin Biologics Business Overview
- 4.12.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio
- 4.12.5 Fuji Film Kyowa Kirin Biologics Recent Developments
- 4.13 Five Prime Therapeutics
- 4.13.1 Five Prime Therapeutics Company Information
- 4.13.2 Five Prime Therapeutics Business Overview
- 4.13.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio
- 4.13.5 Five Prime Therapeutics Recent Developments
5 Global Cancer Angiogenesis Inhibitors Market Scenario by Region
- 5.1 Global Cancer Angiogenesis Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Cancer Angiogenesis Inhibitors Sales by Region: 2027-2032
- 5.3 Global Cancer Angiogenesis Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Angiogenesis Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Angiogenesis Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Cancer Angiogenesis Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Cancer Angiogenesis Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Cancer Angiogenesis Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Angiogenesis Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Cancer Angiogenesis Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Angiogenesis Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Angiogenesis Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Angiogenesis Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Angiogenesis Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Cancer Angiogenesis Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Cancer Angiogenesis Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cancer Angiogenesis Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Angiogenesis Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Angiogenesis Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Angiogenesis Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Angiogenesis Inhibitors Value Chain Analysis
- 8.1.1 Cancer Angiogenesis Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Angiogenesis Inhibitors Production Mode & Process
- 8.2 Cancer Angiogenesis Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Angiogenesis Inhibitors Distributors
- 8.2.3 Cancer Angiogenesis Inhibitors Customers
9 Global Cancer Angiogenesis Inhibitors Analyzing Market Dynamics
- 9.1 Cancer Angiogenesis Inhibitors Industry Trends
- 9.2 Cancer Angiogenesis Inhibitors Industry Drivers
- 9.3 Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges
- 9.4 Cancer Angiogenesis Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst